Oncology News and Research

RSS
Study shows more patients with advanced NSCLC may benefit from pembrolizumab

Study shows more patients with advanced NSCLC may benefit from pembrolizumab

Baxalta announces initial results from ADYNOVATE Phase 3 trial for treatment of hemophilia patients

Baxalta announces initial results from ADYNOVATE Phase 3 trial for treatment of hemophilia patients

MD Anderson study reveals MDSCs as likely target for developing prostate cancer treatments

MD Anderson study reveals MDSCs as likely target for developing prostate cancer treatments

Immunotherapy more effective than chemotherapy in treating patients with advanced lung cancer

Immunotherapy more effective than chemotherapy in treating patients with advanced lung cancer

Roche announces availability of cobas HBVassay for use on cobas 4800 System

Roche announces availability of cobas HBVassay for use on cobas 4800 System

Patients with EGFR-mutated lung cancer benefit more from afatinib as first-line treatment

Patients with EGFR-mutated lung cancer benefit more from afatinib as first-line treatment

Many patients continue working after metastatic cancer diagnosis, study finds

Many patients continue working after metastatic cancer diagnosis, study finds

Halozyme Therapeutics, Lilly sign global collaboration and license agreement

Halozyme Therapeutics, Lilly sign global collaboration and license agreement

Mirati announces initiation of glesatinib Phase 2 clinical trial in NSCLC patients

Mirati announces initiation of glesatinib Phase 2 clinical trial in NSCLC patients

SciClone plans to pursue development of SGX942 in the Greater China market

SciClone plans to pursue development of SGX942 in the Greater China market

Roche's cobas HIV-1 viral load test approved by FDA for use on cobas 6800 and cobas 8800 Systems

Roche's cobas HIV-1 viral load test approved by FDA for use on cobas 6800 and cobas 8800 Systems

CMFT adopts ZedScan system to improve cervical cancer care

CMFT adopts ZedScan system to improve cervical cancer care

Regulus begins RG-125(AZD4076) Phase I study for treatment of NASH in patients with type 2 diabetes/pre-diabetes

Regulus begins RG-125(AZD4076) Phase I study for treatment of NASH in patients with type 2 diabetes/pre-diabetes

Combination therapy can help overcome endocrine resistance in women with advanced breast cancer

Combination therapy can help overcome endocrine resistance in women with advanced breast cancer

Janssen collaborates with Bavarian Nordic to develop, commercialize vaccine for chronic HPV infections

Janssen collaborates with Bavarian Nordic to develop, commercialize vaccine for chronic HPV infections

ALPHAEON announces acquisition of Rocol SA

ALPHAEON announces acquisition of Rocol SA

Chi-Med announces initiation of Phase III sulfatinib registration trial in patients with NETs in China

Chi-Med announces initiation of Phase III sulfatinib registration trial in patients with NETs in China

New nanotechnology approach could transform gliomas from death sentence into treatable condition

New nanotechnology approach could transform gliomas from death sentence into treatable condition

Novel drug candidate prevents nerve cell damage in mouse model of Parkinson's disease

Novel drug candidate prevents nerve cell damage in mouse model of Parkinson's disease

Research opens door to validation studies in multiple tumor types of liquid biopsy

Research opens door to validation studies in multiple tumor types of liquid biopsy

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.